N-terminus acetylation of Semax alters its copper coordination, redox stability, and neuroprotective effects against copper toxicity.
Background
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the adrenocorticotropic hormone (ACTH), known for its neuroprotective and cognitive-enhancing properties. Its biological activity is closely tied to its ability to interact with metal ions like copper (Cu(II)) and zinc (Zn(II)). Dyshomeostasis of these metal ions is implicated in several neurodegenerative diseases. Understanding how structural modifications to Semax, such as N-terminal acetylation, affect its metal-binding capabilities is crucial. This modification could alter its therapeutic potential, particularly its ability to mitigate metal-induced neurotoxicity or act as a targeted ionophore. This research investigates how acetylation modulates the chemical and biological properties of Semax by comparing its coordination with Cu(II) and Zn(II) ions and its effects on neuronal cells.
Study Design
This study compared the metal-binding properties and biological effects of standard Semax and its N-terminally acetylated form, Ac-Semax. The researchers characterized the complex species formed by both peptides with copper (Cu(II)) and zinc (Zn(II)) ions at physiological pH. They assessed the redox potential of the resulting copper complexes and their reactivity against ascorbic acid. Biologically, they evaluated the peptides' ability to protect a human SH-SY5Y neuroblastoma cell line from copper-induced toxicity. Additionally, they used confocal microscopy imaging to observe and compare the effects of Semax and Ac-Semax on Zn(II) influx into the neuroblastoma cells.
Results
N-terminal acetylation significantly altered Semax's interaction with copper. At physiological pH, Ac-Semax formed a primary complex species, [CuLH-2]2-, featuring a distorted CuN3O chromophore with a weak apical methionine sulfur interaction. This structure contrasts sharply with the CuN4 chromophore formed by the unmodified Semax-Cu(II) complex. The modified ligand field in the Ac-Semax complex resulted in a more positive formal redox potential compared to the Semax complex. Consequently, the Cu(II)-Ac-Semax complex was redox-unstable and reactive against ascorbic acid, whereas the native Semax complex was redox-stable.
Critically, the study found that Semax acetylation eliminated its protective effects against Cu(II)-induced toxicity in SH-SY5Y neuroblastoma cells, highlighting the essential role of the free amino terminus for cell protection. Both peptides formed Zn(II) complexes with comparable strength, and acetylation did not affect the rate of Zn(II) influx into cells. Microscopy revealed a punctate distribution of Zn(II) within the cells, suggesting a specific subcellular localization.
Key Findings
- N-terminal acetylation changes Semax's copper complex from a protective
CuN4to aCuN3Ochromophore. - The Cu(II)-Ac-Semax complex is redox-unstable and reactive with ascorbic acid, unlike the stable Cu(II)-Semax complex.
- Ac-Semax failed to protect SH-SY5Y neuroblastoma cells from Cu(II)-induced toxicity, unlike unmodified Semax.
- Acetylation did not alter the ability of Semax to form Zn(II) complexes or facilitate Zn(II) influx into cells.
- A future perspective for Ac-Semax is proposed as an ionophore in antibody-drug conjugates for cancer therapy.
Why It Matters
The findings demonstrate that the free N-terminal amino group of Semax is indispensable for its neuroprotective activity against copper-induced toxicity. For users, this implies that acetylated Semax (Ac-Semax) is not a suitable substitute if the goal is to mitigate metal-related neurotoxicity, as it fails to confer protection and forms a redox-unstable complex with copper. This research clarifies the structure-activity relationship, showing that even a minor modification can fundamentally change a peptide's biological function. While Ac-Semax loses this specific protective property, the paper suggests a new potential application: its ability to transport metal ions could be leveraged, proposing its use as an ionophore in antibody-drug conjugates to deliberately induce metal dyshomeostasis in tumor cells, representing a novel therapeutic strategy.
TitrateLab articles covering Semax
Written by TitrateLab, separately from the study summarized above.
